Jeremy Ryan

26PUBLICATIONS

159CO-AUTHORS

Cancer therapy (excl. chemotherapy and radiation therapy)Predictive and prognostic markersGene and molecular therapyHaematological tumoursMolecular targets

Get your video featured.

Publish with JoVE

Get your video featured.

Publish with JoVE

Publications (26)

Sort by Publication Date:

|May 26, 2026

Dual BCL-xL and BCL-2 Inhibition for Advanced Myeloid Neoplasms: A phase 1 dose-escalation study of Navitoclax, Venetoclax, and Decitabine.

|Dec 26, 2025

Drug-tolerant persisters and immunotherapy persister cells exhibit cross-resistance and share common survival mechanisms.

Maria Davern, Cole J Turner, Daryl Griffin

|Dec 05, 2025

Venetoclax/FluBu2 RIC transplant followed by all-oral venetoclax/decitabine maintenance for poor-risk MDS/AML.

Jacqueline S Garcia, Haesook T Kim, H Moses Murdock

|Nov 15, 2024

Venetoclax plus low-intensity chemotherapy for adults with acute lymphoblastic leukemia.

Marlise R Luskin, Shai Shimony, Julia Keating

|Mar 05, 2024

Acquired Multidrug Resistance in AML Is Caused by Low Apoptotic Priming in Relapsed Myeloblasts.

Elyse A Olesinski, Karanpreet Singh Bhatia, Chuqi Wang

|Jan 10, 2024

Prophylactic maintenance with venetoclax/azacitidine after reduced-intensity conditioning allogeneic transplant for high-risk MDS and AML.

Jacqueline S Garcia, Haesook T Kim, H Moses Murdock

Pageof 5

Frequent Collaborators

14 joint publications

Anthony Letai

Jacqueline S Garcia

Daniel J DeAngelo

Marlise R Luskin

R Coleman Lindsley

H Moses Murdock

Natalia Baran

Venkata L Battula

Michael Andreeff

Qi Zhang

Frequent Collaborators

14 joint publications

Anthony Letai

6 joint publications

Jacqueline S Garcia

5 joint publications

Daniel J DeAngelo

3 joint publications

Marlise R Luskin